News and Events

New immunotherapy approach shows potential in some people with metastatic solid tumors, NIH researchers say

Early findings from a small clinical trial provide evidence that a new cellular immunotherapy approach may be effective in treating metastatic colorectal cancer. In the trial, researchers led by Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch, genetically engineered lymphocytes (a type of white blood cell) from each patient to produce receptors that recognize and attack their specific cancer cells. The personalized immunotherapy shrank tumors in several patients and was able to keep the tumors from regrowing for up to 7 months.

Clinical trial researching combination immunotherapy for endometrial cancer

A trial led by Hoyoung M. Maeng, M.D., Associate Research Physician in the Vaccine Branch, is studying the use of combination drug and vaccine therapy for certain patients with HER2-expressing endometrial cancer.

Clinical trial researching immunotherapy for prostate cancer

A trial led by Ravi A. Madan, M.D., Senior Clinician in the Genitourinary Malignancies Branch, is studying hormone blocking therapy and immunotherapy for prostate cancer.

Artificial intelligence model analyzes tumor images to predict patients’ response to different cancer therapies

Understanding the genetic makeup of a tumor can help doctors recommend the best treatment option for their patients, but molecular sequencing is costly and not accessible to everyone. A new artificial intelligence model called ENLIGHT DEEP-PT could help overcome these challenges.

Celebrating CCR Careers: Jonathan D. Ashwell, M.D.

For nearly 40 years at NCI, Jonathan D. Ashwell, M.D., has worked to understand the mechanisms and consequences of intracellular signaling, primarily in T cells, and how these contribute to disease. Now, the Chief of the Laboratory of Molecular Biology has announced his retirement.

Researchers use artificial intelligence to tease apart subtypes of glioma

A new machine learning algorithm can dig deep into spectral data of brain tumor tissue to reveal genetic mutations, DNA methylation and even the fat content of gliomas. This research advance could help scientists better classify — and one day better treat — brain cancer.

Chengkai Dai appointed to Senior Investigator at CCR

The CCR community congratulates Chengkai Dai, Ph.D., who has been appointed Senior Investigator in the Mouse Cancer Genetics Program. Dai’s laboratory is a pioneer in the field of proteomic instability of cancer. His ongoing research focuses on the molecular mechanisms through which proteomic instability may affect genomic stability, cell invasion and autophagy, areas which hold promise to unveil new molecular pathways that could be targeted in cancer therapy.

Celebrating CCR Careers: Glenn Merlino, Ph.D.

Since first arriving at NCI in 1980, Glenn Merlino, Ph.D., has had a keen interest in unraveling the mechanistic underpinnings of cancer and how this knowledge could be used to improve patient care. Now, after decades of impactful research and mentorship, he is announcing his retirement.

Peter Pinto awarded the AAGUS Barringer Medal

Peter A. Pinto, M.D., Senior Investigator in the Urologic Oncology Branch, was awarded the Barringer Medal by the American Association of Genitourinary Surgeons (AAGUS). The AAGUS is an association of leading academic urologists from the United States, Canada and around the world, dedicated to the study of diseases of the genitourinary system.

Clinical trial researching immunotherapy for bladder cancer

A trial led by Andrea B. Apolo, M.D., Senior Investigator in the Genitourinary Malignancies Branch, is studying combination drug therapy and immunotherapy for bladder and urinary tract cancer.

Breadcrumb